

G-219 1st. 2 - 2415/31245
(Genzyme Docket IG4-9.2(FWC))

PATENT

reference to Table 1 in the claim. Claim 227 has been amended to refer to the sequence of CFTR in Figure 15. The specification also has been amended to change Table 1 to Figure 15 (and Table 2 to Table 1). These changes should obviate the rejection under 35 U.S.C. § 112, ¶ 2.

In view of the amendments herein, as well as the interview on March 10, 1997, it is believed that Claims 226 and 227 are now in condition for allowance. Applicants further request that the present application be sent expeditiously to the Board for declaration of an interference with U.S. Patent No. 5,240,846, in accordance with Applicants' previously submitted Request for Interference Under 37 C.F.R. § 1.607 (paper No. 44).

Respectfully submitted,


Rochelle K. Seide
Patent Office Reg. No. 32,300

BRUMBAUGH, GRAVES, DONOHUE
& RAYMOND
30 Rockefeller Plaza
New York, New York 10112
Telephone: (212) 408-2626
Facsimile: (212) 765-2519

Elizabeth Lassen
GENZYME CORPORATION
One Mountain Road
Framingham, Massachusetts 02701
Telephone: (508) 872-8400
Facsimile: (508) 872-5415

FROM

(TUE) 03. 11' 97 17:06/ST. 16:53/NO. 3561588343 P 11/11

G-219 1st. 2 - 2415/31245
(Genzyme Docket IG4-9.2(FWC))

PATENT

Bruce M. Collins
MATHEWS, WOODBRIDGE & COLLINS, P.A.
100 Thanet Circle, Suite 306
Princeton, New Jersey 08540-3674

028